[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2536830T3 - POLYPEPTIDES - Google Patents

POLYPEPTIDES

Info

Publication number
DK2536830T3
DK2536830T3 DK11707345.2T DK11707345T DK2536830T3 DK 2536830 T3 DK2536830 T3 DK 2536830T3 DK 11707345 T DK11707345 T DK 11707345T DK 2536830 T3 DK2536830 T3 DK 2536830T3
Authority
DK
Denmark
Prior art keywords
polypeptides
Prior art date
Application number
DK11707345.2T
Other languages
Danish (da)
Inventor
Gustav Gaudernack
Anne-Marie Rasmussen
Else Marit Inderberg Suso
Original Assignee
Ultimovacs As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs As filed Critical Ultimovacs As
Application granted granted Critical
Publication of DK2536830T3 publication Critical patent/DK2536830T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK11707345.2T 2010-02-16 2011-02-15 POLYPEPTIDES DK2536830T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10250265 2010-02-16
PCT/EP2011/000980 WO2011101173A1 (en) 2010-02-16 2011-02-15 Polypeptides

Publications (1)

Publication Number Publication Date
DK2536830T3 true DK2536830T3 (en) 2019-10-21

Family

ID=42283642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11707345.2T DK2536830T3 (en) 2010-02-16 2011-02-15 POLYPEPTIDES

Country Status (16)

Country Link
US (5) US9657068B2 (en)
EP (2) EP2536830B1 (en)
JP (2) JP6042211B2 (en)
KR (2) KR102035199B1 (en)
CN (2) CN108383894A (en)
CY (1) CY1122178T1 (en)
DK (1) DK2536830T3 (en)
ES (1) ES2751092T3 (en)
HR (1) HRP20191852T8 (en)
LT (1) LT2536830T (en)
PL (1) PL2536830T3 (en)
PT (1) PT2536830T (en)
RS (1) RS59462B1 (en)
RU (1) RU2581800C2 (en)
SI (1) SI2536830T1 (en)
WO (1) WO2011101173A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN108383894A (en) 2010-02-16 2018-08-10 阿尔特公司 Polypeptide and its application
KR102041381B1 (en) * 2012-03-12 2019-11-27 젬백스 에이에스 Treatment of non-small cell lung carcinoma by active immunotherapy
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP2847213B1 (en) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
CN104487081B (en) 2012-05-11 2017-12-12 珍白斯凯尔有限公司 For preventing or treating cachectic composition
CN108841802B (en) * 2012-05-11 2023-06-09 珍白斯凯尔有限公司 Anti-inflammatory peptides and compositions comprising the same
JP6272853B2 (en) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー，リミティド Cell-penetrating peptide, conjugate containing the same, and composition containing the same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN110092817B (en) * 2012-09-19 2023-04-18 珍白斯凯尔有限公司 Cell penetrating peptide, conjugate comprising the same, and composition comprising the conjugate
JP6510410B2 (en) * 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド Cell penetrating peptide, conjugate containing the same, and composition containing the same
CN113699133B (en) 2012-09-19 2024-07-23 珍白斯凯尔有限公司 Cell penetrating peptides, conjugates comprising same, and uses
CN105263508B (en) 2013-04-19 2019-10-25 珍白斯凯尔有限公司 Treat and prevent the composition of ischemia injury
RU2725744C2 (en) * 2013-06-07 2020-07-03 Джемвакс Энд Каэл Ко., Лтд. Biological markers which can be used in cancer immunotherapy
US10561703B2 (en) 2013-06-21 2020-02-18 Gemvax & Kael Co., Ltd. Method of modulating sex hormone levels using a sex hormone secretion modulator
RU2661596C2 (en) * 2013-10-23 2018-07-17 Джемвакс Энд Каэл Ко., Лтд. Composition for treating and preventing benign prostatic hyperplasia
WO2015072750A1 (en) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 Peptide having anti-inflammatory activity and composition comprising same
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
KR20160097244A (en) * 2013-12-10 2016-08-17 주식회사 젬백스앤카엘 Peptide having antioxidative effect and composition comprising same
ES2809251T3 (en) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composition to treat prostate cancer
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (en) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composition for organ, tissue or cell transplantation, transplant kit and procedure
KR102413243B1 (en) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 Peptides for treating ophthalmopathy and the Composition Comprising the Same
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
EP3305802B1 (en) 2015-05-26 2021-05-12 Gemvax & Kael Co., Ltd. Anti-inflammatory, anti-fibrotic and wound-healing octapeptides and compositions containing the same
KR102638286B1 (en) * 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 Peptides with antiviral activity and compositions containing the same
WO2017147160A1 (en) * 2016-02-23 2017-08-31 Maurizio Zanetti A universal cancer vaccine
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
LT3463436T (en) * 2016-06-02 2024-01-25 Ultimovacs Asa A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
CN106267409B (en) * 2016-07-01 2019-02-01 翁炳焕 AIDS biological therapy reactor
WO2018223092A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
KR20240046703A (en) 2021-06-09 2024-04-09 울티모박스 아베 zygote
WO2024083866A1 (en) 2022-10-17 2024-04-25 Ultimovacs Asa Cancer treatment
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide
WO2024153644A1 (en) * 2023-01-16 2024-07-25 Ospedale San Raffaele S.R.L. T-cell receptors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5695100A (en) 1996-07-19 1997-12-09 O'brien; Vincent E. Baby backpack sun/rain shade device
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6767719B1 (en) 1997-11-26 2004-07-27 Geron Corporation Mouse telomerase reverse transcriptase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
GB2321642B8 (en) 1996-10-01 2006-08-22 Geron Corp Human telomerase reverse transcriptase promoter
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
CN1270634A (en) 1997-07-01 2000-10-18 卡姆比亚生物系统有限责任公司 Vertebrate telomerase genes and proteins and uses thereof
AU1785099A (en) * 1998-01-08 1999-07-26 Chugai Seiyaku Kabushiki Kaisha Novel gene having reverse transcriptase motif
AU759437B2 (en) 1998-01-12 2003-04-17 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
AU1331100A (en) * 1998-10-29 2000-05-22 Dana-Farber Cancer Institute Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
CA2352486A1 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
GB0112342D0 (en) 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
AU2002363231A1 (en) * 2001-10-29 2003-05-12 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
WO2003044169A2 (en) 2001-11-15 2003-05-30 Temple University Of The Commonwealth System Of Higher Education Compositions and methods for reversibly inducing continual growth in normal cells
US20030232409A1 (en) 2002-03-11 2003-12-18 Regents Of The University Of Minnesota Immortal porcine cells
JP2005524409A (en) 2002-05-08 2005-08-18 ファルマシア・イタリア・エス・ピー・エー Methods for identifying chimeric reverse transcriptase and telomerase inhibitors
EP1572090A4 (en) 2002-06-27 2006-11-15 Geron Corp Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
CA2504451A1 (en) 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1874940A1 (en) 2005-04-27 2008-01-09 Cellixe Pty Ltd Transfection of collagen-producing cells
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2007094924A2 (en) 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
EP3489251B1 (en) 2006-07-28 2021-03-17 The Trustees of the University of Pennsylvania Hiv consensus proteins and vaccines made therefrom
EP1994942A1 (en) 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
US20090142408A1 (en) 2007-07-23 2009-06-04 Telomolecular Corporation Telomerase delivery by biodegradable Nanoparticle
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
LT2310044T (en) * 2008-06-16 2016-12-27 Mediolanum Farmaceutici S.P.A. Anti-tumor immunotherapy
US8252282B2 (en) 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
WO2010018731A2 (en) 2008-08-12 2010-02-18 Japan Health Sciences Foundation A mammalian rna dependent rna polymerase
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
JPWO2010084970A1 (en) 2009-01-23 2012-07-19 国立大学法人大阪大学 Feeder cells for target cell induction
CN108383894A (en) 2010-02-16 2018-08-10 阿尔特公司 Polypeptide and its application
EP2578678B1 (en) 2010-05-31 2015-10-28 Eisai R&D Management Co., Ltd. Method for producing tumor cell
EP2402038B1 (en) 2010-07-02 2016-05-25 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Telomerase reverse transcriptase for protection against ageing
LT3463436T (en) 2016-06-02 2024-01-25 Ultimovacs Asa A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Also Published As

Publication number Publication date
US20230277641A1 (en) 2023-09-07
CN102858964A (en) 2013-01-02
US9657068B2 (en) 2017-05-23
JP2016183169A (en) 2016-10-20
EP3581649A1 (en) 2019-12-18
RU2012139432A (en) 2014-03-27
HRP20191852T8 (en) 2021-10-01
US20200121771A1 (en) 2020-04-23
EP2536830A1 (en) 2012-12-26
US11529403B2 (en) 2022-12-20
HRP20191852T1 (en) 2019-12-27
JP2013519385A (en) 2013-05-30
RS59462B1 (en) 2019-11-29
CN108383894A (en) 2018-08-10
US20170232087A1 (en) 2017-08-17
CN102858964B (en) 2018-10-02
SI2536830T1 (en) 2019-12-31
JP6444336B2 (en) 2018-12-26
ES2751092T3 (en) 2020-03-30
WO2011101173A1 (en) 2011-08-25
US20170232088A1 (en) 2017-08-17
LT2536830T (en) 2019-11-11
US10383928B2 (en) 2019-08-20
EP2536830B1 (en) 2019-07-17
KR20130024888A (en) 2013-03-08
JP6042211B2 (en) 2016-12-14
US20130129760A1 (en) 2013-05-23
PL2536830T3 (en) 2020-02-28
PT2536830T (en) 2019-10-29
RU2581800C2 (en) 2016-04-20
CY1122178T1 (en) 2020-11-25
KR20180088756A (en) 2018-08-06
KR102035199B1 (en) 2019-10-22
US11998595B2 (en) 2024-06-04

Similar Documents

Publication Publication Date Title
DK2536830T3 (en) POLYPEPTIDES
BR112012028556A2 (en) INDOS
DK3225404T3 (en) FLUIDPATRON
DE102011100241A8 (en) Nitridhalbleiterbauteil
BR112013017629A2 (en) recombinant laminin-521
CR20130111A (en) TRIAZINA-OXIDIAZOLES
DE10170954T8 (en) Mikrowellendruckgarer
DE112011104226A5 (en) Käfigmutter
DE102011117046A8 (en) Doppelkupplungswindungsgetriebe
DE112011102080A5 (en) Kupplungszentralausrücker
DE112011101226A5 (en) Linearwegmesssystem
DK2442899T3 (en) Rotordisc
DK2539163T3 (en) Tyrevalve
DE102011002623A8 (en) Ventilsteuerzeitversteller
DE112011102711A5 (en) Hydrostataktor
DK2448659T3 (en) Rotordisc
DK2447426T3 (en) Washlet
DE102010019119B8 (en) Cuttermesser
DE102010038420A8 (en) Reinigungungsvorrichtung
DK2596072T3 (en) BOR-JUNCTION-SUSPENSION
DK2521486T3 (en) Palpometer
DE102010035554B8 (en) Fußtüröffner
CO6801789A2 (en) N-Hetarylmethyl pyrazolylcarboxamides
DE112011101796A5 (en) Redoxakkumulatoranlage
BR112013009679A2 (en) peptide